BACKGROUND: The ELAC2 gene has been proposed to be a prostate cancer susceptibility gene and is being referred to as HPC2, in part because three case-control studies suggested that two common polymorphisms (Ser217Leu and Ala541Thr) are associated with risk. However, four subsequent larger studies have not confirmed this association. In five of the seven total studies, subject selection was influenced by prostate-specific antigen (PSA) levels. We examined the association and possible effect of subject selection in a larger study and a meta-analysis. METHODS: In a population-based study in Australia, 825 case patients and 732 control subjects were genotyped for the Ser217Leu and Ala541Thr polymorphisms of ELAC2. Odds ratios (ORs) for prostate cancer were estimated by unconditional logistic and polytomous regression. A meta-analysis was conducted combining our data with those from seven published studies. The association of genotype with the logarithm of plasma PSA levels in control subjects was analyzed by linear regression. RESULTS: The ORs for prostate cancer were 0.74 (95% confidence interval [CI] = 0.50 to 1.09) for Leu217 homozygotes and 1.01 (95% CI = 0.68 to 1.50) for Thr541 heterozygotes and homozygotes compared with Ser217 and Ala541 homozygotes, respectively. ORs were not changed by excluding control subjects with elevated PSA levels. Among control subjects, there were no statistically significant associations between genotype frequencies and PSA level for either polymorphism (both P>.4). The meta-analysis gave pooled OR estimates of 1.04 (95% CI = 0.85 to 1.26) for Leu217 homozygotes and 1.18 (OR = 0.98 to 1.42) for Thr541 homozygotes and heterozygotes. CONCLUSION: There is no evidence that either ELAC2 polymorphism is associated with prostate cancer or PSA level.
BACKGROUND: The ELAC2 gene has been proposed to be a prostate cancer susceptibility gene and is being referred to as HPC2, in part because three case-control studies suggested that two common polymorphisms (Ser217Leu and Ala541Thr) are associated with risk. However, four subsequent larger studies have not confirmed this association. In five of the seven total studies, subject selection was influenced by prostate-specific antigen (PSA) levels. We examined the association and possible effect of subject selection in a larger study and a meta-analysis. METHODS: In a population-based study in Australia, 825 case patients and 732 control subjects were genotyped for the Ser217Leu and Ala541Thr polymorphisms of ELAC2. Odds ratios (ORs) for prostate cancer were estimated by unconditional logistic and polytomous regression. A meta-analysis was conducted combining our data with those from seven published studies. The association of genotype with the logarithm of plasma PSA levels in control subjects was analyzed by linear regression. RESULTS: The ORs for prostate cancer were 0.74 (95% confidence interval [CI] = 0.50 to 1.09) for Leu217 homozygotes and 1.01 (95% CI = 0.68 to 1.50) for Thr541 heterozygotes and homozygotes compared with Ser217 and Ala541 homozygotes, respectively. ORs were not changed by excluding control subjects with elevated PSA levels. Among control subjects, there were no statistically significant associations between genotype frequencies and PSA level for either polymorphism (both P>.4). The meta-analysis gave pooled OR estimates of 1.04 (95% CI = 0.85 to 1.26) for Leu217 homozygotes and 1.18 (OR = 0.98 to 1.42) for Thr541 homozygotes and heterozygotes. CONCLUSION: There is no evidence that either ELAC2 polymorphism is associated with prostate cancer or PSA level.
Authors: Elizabeth A Tindall; Hoa N Hoang; Melissa C Southey; Dallas R English; John L Hopper; Graham G Giles; Gianluca Severi; Vanessa M Hayes Journal: BMC Cancer Date: 2010-02-25 Impact factor: 4.430
Authors: Robert J MacInnis; Daniel F Schmidt; Enes Makalic; Gianluca Severi; Liesel M FitzGerald; Matthias Reumann; Miroslaw K Kapuscinski; Adam Kowalczyk; Zeyu Zhou; Benjamin Goudey; Guoqi Qian; Quang M Bui; Daniel J Park; Adam Freeman; Melissa C Southey; Ali Amin Al Olama; Zsofia Kote-Jarai; Rosalind A Eeles; John L Hopper; Graham G Giles Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-18 Impact factor: 4.254
Authors: G Severi; B A Shannon; H N Hoang; L Baglietto; D R English; J L Hopper; J Pedersen; M C Southey; R Sinclair; R J Cohen; G G Giles Journal: Br J Cancer Date: 2010-07-06 Impact factor: 7.640
Authors: Rosalind A Eeles; Zsofia Kote-Jarai; Ali Amin Al Olama; Graham G Giles; Michelle Guy; Gianluca Severi; Kenneth Muir; John L Hopper; Brian E Henderson; Christopher A Haiman; Johanna Schleutker; Freddie C Hamdy; David E Neal; Jenny L Donovan; Janet L Stanford; Elaine A Ostrander; Sue A Ingles; Esther M John; Stephen N Thibodeau; Daniel Schaid; Jong Y Park; Amanda Spurdle; Judith Clements; Joanne L Dickinson; Christiane Maier; Walther Vogel; Thilo Dörk; Timothy R Rebbeck; Kathleen A Cooney; Lisa Cannon-Albright; Pierre O Chappuis; Pierre Hutter; Maurice Zeegers; Radka Kaneva; Hong-Wei Zhang; Yong-Jie Lu; William D Foulkes; Dallas R English; Daniel A Leongamornlert; Malgorzata Tymrakiewicz; Jonathan Morrison; Audrey T Ardern-Jones; Amanda L Hall; Lynne T O'Brien; Rosemary A Wilkinson; Edward J Saunders; Elizabeth C Page; Emma J Sawyer; Stephen M Edwards; David P Dearnaley; Alan Horwich; Robert A Huddart; Vincent S Khoo; Christopher C Parker; Nicholas Van As; Christopher J Woodhouse; Alan Thompson; Tim Christmas; Chris Ogden; Colin S Cooper; Melissa C Southey; Artitaya Lophatananon; Jo-Fen Liu; Laurence N Kolonel; Loic Le Marchand; Tiina Wahlfors; Teuvo L Tammela; Anssi Auvinen; Sarah J Lewis; Angela Cox; Liesel M FitzGerald; Joseph S Koopmeiners; Danielle M Karyadi; Erika M Kwon; Mariana C Stern; Roman Corral; Amit D Joshi; Ahva Shahabi; Shannon K McDonnell; Thomas A Sellers; Julio Pow-Sang; Suzanne Chambers; Joanne Aitken; R A Frank Gardiner; Jyotsna Batra; Mary Anne Kedda; Felicity Lose; Andrea Polanowski; Briony Patterson; Jürgen Serth; Andreas Meyer; Manuel Luedeke; Klara Stefflova; Anna M Ray; Ethan M Lange; Jim Farnham; Humera Khan; Chavdar Slavov; Atanaska Mitkova; Guangwen Cao; Douglas F Easton Journal: Nat Genet Date: 2009-09-20 Impact factor: 38.330
Authors: Christiane M Robbins; Wenndy Hernandez; Chiledum Ahaghotu; James Bennett; Gerald Hoke; Terry Mason; Curtis A Pettaway; Srinivasan Vijayakumar; Sally Weinrich; Paulette Furbert-Harris; Georgia Dunston; Isaac J Powell; John D Carpten; Rick A Kittles Journal: Prostate Date: 2008-12-01 Impact factor: 4.104
Authors: Clay E S Comstock; Michael A Augello; Ruth Pe Benito; Jason Karch; Thai H Tran; Fransiscus E Utama; Elizabeth A Tindall; Ying Wang; Craig J Burd; Eric M Groh; Hoa N Hoang; Graham G Giles; Gianluca Severi; Vanessa M Hayes; Brian E Henderson; Loic Le Marchand; Laurence N Kolonel; Christopher A Haiman; Raffaele Baffa; Leonard G Gomella; Erik S Knudsen; Hallgeir Rui; Susan M Henshall; Robert L Sutherland; Karen E Knudsen Journal: Clin Cancer Res Date: 2009-08-25 Impact factor: 12.531
Authors: Liesel M FitzGerald; Briony Patterson; Russell Thomson; Andrea Polanowski; Stephen Quinn; Jesper Brohede; Timothy Thornton; David Challis; David A Mackey; Terence Dwyer; Simon Foote; Garry N Hannan; James Stankovich; James D McKay; Joanne L Dickinson Journal: Eur J Hum Genet Date: 2008-10-01 Impact factor: 4.246